LABP vs. ACHL, AWH, SNSE, GOSS, ADVM, ANL, NATR, ADCT, ATAI, and ME
Should you be buying Landos Biopharma stock or one of its competitors? The main competitors of Landos Biopharma include Achilles Therapeutics (ACHL), Aspira Women's Health (AWH), Sensei Biotherapeutics (SNSE), Gossamer Bio (GOSS), Adverum Biotechnologies (ADVM), Adlai Nortye (ANL), Nature's Sunshine Products (NATR), ADC Therapeutics (ADCT), Atai Life Sciences (ATAI), and 23andMe (ME). These companies are all part of the "medical" sector.
Achilles Therapeutics (NASDAQ:ACHL) and Landos Biopharma (NASDAQ:LABP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, community ranking, earnings and dividends.
56.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 49.1% of Landos Biopharma shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by insiders. Comparatively, 1.3% of Landos Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Achilles Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 334.78%. Landos Biopharma has a consensus target price of $20.42, suggesting a potential downside of 10.95%. Given Landos Biopharma's higher probable upside, research analysts plainly believe Achilles Therapeutics is more favorable than Landos Biopharma.
Achilles Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Landos Biopharma has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500.
In the previous week, Achilles Therapeutics had 2 more articles in the media than Landos Biopharma. MarketBeat recorded 3 mentions for Achilles Therapeutics and 1 mentions for Landos Biopharma. Landos Biopharma's average media sentiment score of 1.44 beat Achilles Therapeutics' score of 0.94 indicating that Achilles Therapeutics is being referred to more favorably in the media.
Landos Biopharma has higher revenue and earnings than Achilles Therapeutics. Landos Biopharma is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Landos Biopharma's return on equity of -42.95% beat Achilles Therapeutics' return on equity.
Landos Biopharma received 13 more outperform votes than Achilles Therapeutics when rated by MarketBeat users. Likewise, 62.50% of users gave Landos Biopharma an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote.
Summary
Achilles Therapeutics beats Landos Biopharma on 11 of the 15 factors compared between the two stocks.
Get Landos Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LABP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Landos Biopharma Competitors List
Related Companies and Tools
